Market closedNon-fractional
Axogen/AXGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Axogen
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
Ticker
AXGN
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Alachua, United States
Employees
427
Website
www.axogeninc.com
Axogen Metrics
BasicAdvanced
$408M
Market cap
-
P/E ratio
-$0.49
EPS
1.02
Beta
-
Dividend rate
Price and volume
Market cap
$408M
Beta
1.02
Financial strength
Current ratio
3.43
Quick ratio
1.825
Long term debt to equity
75.602
Total debt to equity
77.367
Interest coverage (TTM)
-3.63%
Management effectiveness
Return on assets (TTM)
-6.21%
Return on equity (TTM)
-22.32%
Valuation
Price to revenue (TTM)
2.453
Price to book
4.35
Price to tangible book (TTM)
4.58
Price to free cash flow (TTM)
-18.041
Growth
Revenue change (TTM)
13.51%
Earnings per share change (TTM)
-16.37%
3-year revenue growth (CAGR)
11.20%
3-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about Axogen
Analyst Ratings
Majority rating from 6 analysts.
Axogen Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
-3.73%
Net income
-$6.6M
73.68%
Profit margin
-15.98%
80.56%
Axogen Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
$0.01
-$0.06
-$0.06
-
Expected
-$0.13
-$0.06
-$0.10
-$0.07
-$0.04
Surprise
-76.92%
-116.00%
-37.82%
-11.76%
-
Axogen News
AllArticlesVideos
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
GlobeNewsWire·4 days ago
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewsWire·4 weeks ago
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Axogen stock?
Axogen (AXGN) has a market cap of $408M as of July 27, 2024.
What is the P/E ratio for Axogen stock?
The price to earnings (P/E) ratio for Axogen (AXGN) stock is 0 as of July 27, 2024.
Does Axogen stock pay dividends?
No, Axogen (AXGN) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Axogen dividend payment date?
Axogen (AXGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Axogen?
Axogen (AXGN) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Axogen stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.